Wegovy weight loss data: what the trials actually found

You're staring at a percentage figure and wondering what it means for you

Most weight loss data gets reported as a single average, and that average can obscure a wide range of individual results. In STEP 1 (the pivotal phase 3 trial published in the New England Journal of Medicine) 1,961 adults with obesity (BMI 30 or above, or 27 or above with at least one weight-related condition) were randomised across 16 countries. After 68 weeks, those on semaglutide 2.4mg lost an average of around 15% of their initial body weight. Those on placebo lost around 2.4%. Both groups followed a reduced-calorie diet and increased activity, which matters, the medicine doesn't operate in isolation.

What the average doesn't show is the spread. Roughly a third of participants lost 20% or more. Others lost considerably less. Starting weight, adherence, gastric tolerance and metabolic factors all shaped individual outcomes. That spread is one reason a personalised clinical assessment matters far more than comparing yourself to a headline figure. Take a moment to check whether the trial population described matches your own situation, it's a quick but useful gut-check before drawing conclusions about your likely results.

The trial also had a stopping point. Weight loss on semaglutide is not indefinite; it typically slows after roughly 60 weeks and stabilises. Participants who completed STEP 1 and then stopped treatment regained most of their lost weight within a year in a follow-up study. That finding shifted how clinicians think about duration, which is part of why NICE, in its guidance on semaglutide (TA875), capped NHS use at a maximum of two years within specialist services.

What the newer 7.2mg data adds to the picture

When Wegovy at the 2.4mg dose was approved, it was the highest licensed semaglutide dose for weight management. That changed. The MHRA approved a 7.2mg maintenance dose in January 2026 and, on 14 April 2026, cleared a dedicated single-dose 7.2mg pen, a built-in auto-dosing mechanism with a covered needle that locks after use. Trials at this higher dose reported around 20.7% average weight loss over 72 weeks, meaningfully narrowing the gap between semaglutide and tirzepatide (Mounjaro), which produced around 20–21% at its highest dose in the SURMOUNT-1 trial.

The 7.2mg licence applies specifically to adults with a BMI of 30 or above, not to the lower BMI-plus-comorbidity threshold. Dose titration still begins at 0.25mg; reaching 7.2mg takes several months of gradual increases under prescriber supervision. Never assume you'll reach or tolerate the highest dose, the prescriber adjusts the schedule based on how you're responding and what your body is signalling along the way.

The gov.uk announcement about the single-dose 7.2mg semaglutide pen sets out the full approval detail. Specific dose availability is always confirmed at consultation, since stock formats can change.

Wegovy tablets: the data behind the UK's first oral GLP-1 approval

On 11 June 2026, the MHRA approved Wegovy in tablet form (oral semaglutide co-formulated with an absorption enhancer) making it the first oral GLP-1 medicine licensed for weight management in the UK. The UK was first in Europe to reach that milestone. The pivotal phase 3 trial, OASIS 4, enrolled 307 adults over 64 weeks. Average weight loss was around 13.6% versus about 2.4% with placebo. Among participants who adhered fully to the treatment protocol, average loss reached around 16.6%. That higher figure is only meaningful if framed correctly: it describes a fully-adherent subgroup, not the overall population.

The most common side effects in OASIS 4 were gastrointestinal, reported in about 74% of the semaglutide group versus 42% in the placebo group, generally mild to moderate and tending to settle over time. The dosing ladder runs from 1.5mg through 4mg and 9mg to the 25mg maintenance dose, with a minimum of one month at each level. The tablet is taken first thing in the morning on an empty stomach with a small amount of plain water; food, drink and other medicines should follow at least 30 minutes later. No refrigeration is needed, which removes a practical hurdle that some people find significant with the injectable form. For a broader overview of how the injectable and tablet options compare, the Wegovy weight loss page covers both in detail.

Putting the data in the right frame before you make a decision

Clinical trial data is the best evidence available, but it describes a study population, not you specifically. Your prescriber will weigh your BMI, your health history, any medicines you already take, and your goals before recommending a treatment or a starting dose. That's not a bureaucratic hurdle; it's the step that makes the data relevant to your individual situation rather than to a statistical average. If you want to dig into the technical detail behind the medicine, the Wegovy data sheet sets out the full prescribing information in one place.

If you're weighing up how Wegovy fits into your wider weight management plan, or considering how its trial results compare with other licensed options, that's exactly the kind of question our prescribers work through with patients at consultation. There's no cost for the assessment, and our clinical team reviews every submission the same day it's submitted, not by a piece of software but by a named prescriber. You can read more about how we work on the about us page, or look at all our weight loss treatments if you'd like to see what's available before you start.

Cost is a factor for most people. The Wegovy prices page explains what a private prescription realistically involves, and what a transparent price should include. If you're ready to find out whether you're clinically suitable, start your free consultation and a prescriber will review your answers the same day.